Last updated: 2026-10-14 14:58:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
AnaptysBio, Inc. (ANAB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $46.72, with a market capitalisation of $1.38B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $30.27 to $73.30. This page covers its latest market performance, valuation, price trends and company information.
$1.38B | |
$45.25 | |
$134.00 | |
$10.00 | |
$45.59 | |
111.96K | |
541.15K | |
-- | |
$73.30 | |
$30.27 | |
-- | |
-- |
AnaptysBio, Inc. (ANAB) is currently trading at $46.72 as of 2026-10-14 14:57:00, up 2.47% ($1.13) from the previous close of $45.59
During today's regular trading session, ANAB has traded between $10.00 and $134.00, with a trading volume of 111.96K shares. The current price is near the lower end of today's range.
Over the past seven days, AnaptysBio, Inc. (ANAB) moved from $49.20 to $46.72, representing a decline of 5.05% ($2.48).
The stock traded between $44.74 and $49.84 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 546.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.2%
ANAB is currently trading at $46.72, placing it 38.2% of the way from its 52-week low of $30.27 to its 52-week high of $73.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 104 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AnaptysBio, Inc. (ANAB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.